Pathologic Processes clinical trials
The registry lists 191 studies for Pathologic Processes across more than 10 countries. 32 are recruiting or about to start. 9 of them are mainly about Pathologic Processes (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Pathologic Processes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Vertex Pharmaceuticals Incorporated (4) · Pfizer (3) · Bausch Health Americas, Inc. (3) · Aeris Therapeutics (3) · University of Colorado, Denver (3) · AO GENERIUM (3) · Bluejay Diagnostics, Inc. (3) · Grifols Therapeutics LLC (2)
What is being tested here
Drugs under test in Pathologic Processes studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 · Angiogenesis inhibitors 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) · Phase 3 · Qilu Pharmaceutical Co., Ltd.
- Sep 2027A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) · Phase 3 · Grifols Therapeutics LLC
- Nov 2027A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer · Phase 3 · Eli Lilly and Company
- Nov 2026Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) · Medtronic Cardiac Ablation Solutions
- Nov 2026Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers · Tides Medical
- Nov 2026Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs · C5 Biomedical
- Dec 2026Mesenchymal Stem Cells for Frailty Syndrome · Meribank Biotech Co., Ltd.
- Dec 2026Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study · Bluejay Diagnostics, Inc.
- Dec 2026Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study · Bluejay Diagnostics, Inc.
- Dec 2026Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation · University of Rochester
Who these studies take
Of the 30 Pathologic Processes studies recruiting now, 15 (50%) set no upper age limit and 4 (13%) stop at 75 or younger. 2 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (7%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (7%) | 2 (7%) |
| 18 | 29 (97%) | 29 (97%) |
| 30 | 29 (97%) | 29 (97%) |
| 40 | 30 (100%) | 30 (100%) |
| 50 | 30 (100%) | 30 (100%) |
| 65 | 30 (100%) | 30 (100%) |
| 75 | 26 (87%) | 26 (87%) |
| 85 | 22 (73%) | 22 (73%) |
Across all 191 studies, recruiting or not: 25% stop at 75 or younger and 16% at 65; 15% take children; 5% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Pathologic Processes studies take
Of 23 phase 3 interventional studies under Pathologic Processes, half reached primary completion within 39 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 3 | 39 mo25–68 · 23 studies | — | — |
| Interventional, no phase | 31 mo23–41 · 37 studies | — | — |
| Observational | 36 mo12–85 · 18 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 11, 2026.
Results posted1
- Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration InterventionOct 14, 2026NCT06374225
Newly registered2
- Long-Term Clinical, Health Economic, and Process Evaluation of Intensive Technology-Integrated Motor Rehabilitation in Chronic Neurological Conditions (INTeRAcT-bis)Nov 3, 2026NCT07912320
- This Study is the Clinical Validation Study for Validation for the Digital Pathology System 'SGi 1.0 + EPW 1.0 + Compatible Clinical Displays'Oct 20, 2026NCT07881874
Studies
Recruiting first, then most recently updated. Showing 50 of 191. Browse all 191 → or search them.
- Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesRecruitingNCT07098806Phase 1/21 country
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 329 countries
- Long-Term Clinical, Health Economic, and Process Evaluation of Intensive Technology-Integrated Motor Rehabilitation in Chronic Neurological Conditions (INTeRAcT-bis)Enrolling by invitationNCT07912320Not applicable1 country
- A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in GermanyRecruitingNCT071023681 country
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsRecruitingNCT07654283Phase 26 countries
- A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)RecruitingNCT07555483Phase 39 countries
- Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)RecruitingNCT07585968Not applicable1 country
- A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)RecruitingNCT07431112Phase 19 countries
- This Study is the Clinical Validation Study for Validation for the Digital Pathology System 'SGi 1.0 + EPW 1.0 + Compatible Clinical Displays'RecruitingNCT078818741 country
- SPYRAL GEMINI Pilot StudyRecruitingNCT06907147Not applicable6 countries
- Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific RegionRecruitingNCT07370207Phase 27 countries
- Transcutaneous Auricular Vagus Enhanced Recovery in the NeuroICURecruitingNCT07219108Not applicable1 country
- Labyrinthin Vaccination in Veterans With Lung AdenocarcinomaNot yet recruitingNCT07859592Phase 21 country
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSRecruitingNCT07197944Phase 314 countries
- Autologous Bone Marrow Aspirate Treatment for Early-Stage OsteonecrosisRecruitingNCT06123481Not applicable1 country
- Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)RecruitingNCT06703489Not applicable1 country
- Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility StudyRecruitingNCT07759115Not applicable1 country
- Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)RecruitingNCT054523561 country
- Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeRecruitingNCT07216443Phase 21 country
- Auricular VNS Following Intracerebral HemorrhageRecruitingNCT06799390Not applicable1 country
- Biomarkers in InfectionRecruitingNCT025454781 country
- Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection SpecimensRecruitingNCT06252129Not applicable1 country
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary FibrosisRecruitingNCT05975983Phase 21 country
- Budesonide As a Treatment for Functional DyspepsiaRecruitingNCT06841406Phase 41 country
- Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal SurgeryRecruitingNCT04256798Phase 35 countries
- Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot UlcersRecruitingNCT06681428Not applicable1 country
- Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and LactuloseRecruitingNCT04073290Phase 42 countries
- Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUsRecruitingNCT06674980Not applicable1 country
- Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic ShockRecruitingNCT05969275Phase 21 country
- Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy StudyRecruitingNCT051754691 country
- Suture Techniques to Reduce the Incidence of Incisional Hernia: LTFU STITCH TrialRecruitingNCT06066385Not applicable1 country
- Atrial Fibrillation and Diabetes MellitusRecruitingNCT058739201 country
- Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected AdultsCompletedNCT007764121 country
- Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Active, not recruitingNCT05797246Phase 21 country
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 313 countries
- Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration InterventionCompletedNCT06374225Not applicable1 country
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT04722887Phase 1/21 country
- Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation StudyActive, not recruitingNCT066548951 country
- Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot StudyActive, not recruitingNCT074255871 country
- GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLTerminatedNCT04601584Phase 1/21 country
- Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel SyndromeCompletedNCT06271538Phase 41 country
- Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionActive, not recruitingNCT02682511Phase 22 countries
- Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett SyndromeActive, not recruitingNCT07480564Phase 31 country
- MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central NorwayActive, not recruitingNCT039621271 country
- Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)CompletedNCT06162728Phase 1/22 countries
- Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel SyndromeActive, not recruitingNCT07228403Phase 37 countries
- Vorasidenib Expanded Access ProgramApproved for marketingNCT05592743
- A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)Active, not recruitingNCT05606614Phase 32 countries
- The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The TezEx StudyCompletedNCT066665041 country
- A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett SyndromeActive, not recruitingNCT05898620Phase 33 countries